|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
2.03/5.24
|
企業價值
261.87B
|
資產負債 |
每股賬面淨值
12.08
|
現金流量 |
現金流量率
0.04
|
損益表 |
收益
45.81B
|
每股收益
14.35
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/16 11:21 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue. |